CD274 and non-small cell lung carcinoma: Moreover, a study suggested that analyzing PD-L1 carried by EVs in NSCLC patients treated with immune checkpoint inhibitors is a potential strategy for predicting treatment outcomes and prognosis in cancer patients [212].